Evogene (EVGN) Capital Expenditures (2013 - 2026)

Evogene has disclosed Capital Expenditures across 14 years of filings, most recently posting -$2000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 98.35% year-over-year to -$2000.0; the TTM figure through Mar 2026 stood at -$6000.0 (up 98.5% YoY), while the FY2025 annual figure was $2000.0, up 100.32% from the prior year.
• Capital Expenditures came in at -$2000.0 for Q1 2026 at Evogene, up from -$6000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $28000.0 in Q3 2024 to a low of -$442000.0 in Q1 2022.
• Average Capital Expenditures over 5 years is -$147235.3, with a median of -$124000.0 recorded in 2023.
• The largest YoY upside for Capital Expenditures was 112.96% in 2024 against a maximum downside of 274.42% in 2024.
• Over 5 years, Capital Expenditures stood at -$199000.0 in 2022, then soared by 56.78% to -$86000.0 in 2023, then tumbled by 274.42% to -$322000.0 in 2024, then jumped by 98.14% to -$6000.0 in 2025, then jumped by 66.67% to -$2000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$2000.0 in Q1 2026, -$6000.0 in Q4 2025, and -$9000.0 in Q3 2025.